K-ras Mutation in Endometrium of Breast Cancer Patients Treated with Tamoxifen and Toremifene
Author Information
Author(s): Hachisuga T, Tsujioka H, Horiuchi S, Udou T, Emoto M, Kawarabayashi T
Primary Institution: Fukuoka University
Hypothesis
The study investigates differences in the frequency of K-ras mutations in endometrial samples of patients treated with tamoxifen or toremifene.
Conclusion
K-ras mutations were found in 40.7% of tamoxifen-treated endometrial samples, while only one mutation was found in toremifene-treated samples, suggesting lower genotoxicity of toremifene.
Supporting Evidence
- K-ras mutation was found in 35 out of 86 tamoxifen-treated endometrial samples.
- Only one K-ras mutation was detected in the 21 toremifene-treated patients.
- The presence of K-ras mutation was significantly influenced by the duration of tamoxifen treatment.
Takeaway
This study looked at how a gene mutation related to cancer was found more often in women taking tamoxifen than in those taking a similar drug called toremifene.
Methodology
DNA was extracted from endometrial cytologic samples and K-ras mutations were detected using enriched PCR and an enzyme-linked mini-sequence assay.
Potential Biases
Potential bias due to the selection of patients and the retrospective nature of the study.
Limitations
The study had a small sample size for toremifene-treated patients and did not assess long-term effects post-treatment.
Participant Demographics
Patients included 86 tamoxifen-treated and 21 toremifene-treated breast cancer patients, with ages ranging from 27 to 86 years.
Statistical Information
P-Value
p<0.003
Statistical Significance
p<0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website